SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study.
Volume: 37, Issue: 15_suppl, Pages: 4092 - 4092
Published: May 20, 2019
Abstract
4092 Background: SHR1210 is a humanized anti-programmed cell death receptor 1 (PD-1) antibody. We conducted a single arm exploratory study to evaluate the efficacy and safety of SHR-1210 plus gemcitabine and oxaliplatin (GEMOX) as first line treatment in patients (pts) with biliary tract cancer (BTC). Methods: Pts received SHR-1210 (3mg/kg, total dose ≤200mg, ivd, D1/2W) combined with gemcitabine (800 mg/m2, ivd, D1/2W) and oxaliplatin (85mg/m2,...
Paper Details
Title
SHR-1210 plus GEMOX as first line treatment in biliary tract cancer: Results from a single-arm exploratory study.
Published Date
May 20, 2019
Journal
Volume
37
Issue
15_suppl
Pages
4092 - 4092
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History